Recombinant A2-specific TNFα-specific antibodies
AssigneesCentocor, Inc., New York University
InventorsJunming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
Life of this patent
Estimating the term…
Abstract
Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
Claims20
An isolated recombinant anti-TNF-α antibody or antigen-binding fragment thereof, said antibody comprising a human constant region, wherein said antibody or antigen-binding fragment (i) competitively inhibits binding of A2 (ATCC Accession No. PTA-7045) to human tumor necrosis factor TNF α, and (ii) binds to human TNF-α with an affinity of at least 1×108 liter/mole, measured as an association constant (Ka).
An isolated recombinant anti-TNF-α antibody or antigen-binding fragment thereof, said antibody comprising a human IgG1 constant region, wherein said antibody or antigen-binding fragment (i) competitively inhibits binding of A2 (ATCC Accession No. PTA-7045) to human TNFα, and (ii) binds to human TNF-α with an affinity of at least 1×108 liter/mole, measured as an association constant (Ka).
An isolated recombinant anti-TNF-α antibody or antigen-binding fragment thereof, said antibody comprising a human constant region, wherein said antibody or antigen-binding fragment (i) comprises the antigen-binding regions of A2 (ATCC Accession No. PTA-7045), and (ii) binds to human TNF-α with an affinity of at least 1×108 liter/mole, measured as an association constant (Ka).
An isolated recombinant anti-TNF-α antibody or antigen-binding fragment thereof, said antibody comprising a human IgG1 constant region, wherein said antibody or antigen-binding fragment (i) comprises the antigen-binding regions of A2 (ATCC Accession No. PTA-7045), and (ii) binds to human TNF-α with an affinity of at least 1×108 liter/mole, measured as an association constant (Ka).
An isolated recombinant anti-TNF-α antibody or antigen-binding fragment thereof, said antibody comprising a human IgG4 constant region, wherein said antibody or antigen-binding fragment (i) competitively inhibits binding of A2 (ATCC Accession No. PTA-7045) to human TNFα, and (ii) binds to human TNF-α with an affinity of at least 108 liter/mole, measured as an association constant (Ka).
An isolated recombinant anti-TNF-α antibody or antigen-binding fragment thereof, said antibody comprising a human IgG4 constant region, wherein said antibody or antigen-binding fragment (i) comprises the antigen-binding regions of A2 (ATCC Accession No. PTA-7045), and (ii) binds to human TNF-α with an affinity of at least 1×108 liter/mole, measured as an association constant (Ka).
Dependencies are inferred from the claim text.